Dr. Dung Le on Biomarker for PD-1 Agents in CRC

Video

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Dung T. Le, MD, assistant professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Le discusses a study that examined the PD-1 blockade of tumors with mismatch repair deficiency. These specific tumors have mutations that could potentially be recognizable by the immune system, she says.

The study included three cohorts: colorectal cancer tumors with mismatch repair deficiency, colorectal cancer tumors with mismatch repair proficiency, and any tumor type with mismatch repair deficiency. Researchers saw that responses were restricted to mismatch repair deficiency, with a 62% response rate in the cohort of patients with CRC. The cohort with mismatch repair proficiency had a 0% response rate, while the third cohort with any tumor type had a 16% response rate. These were durable responses, Le says.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD